Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors.

Scientific reports - 16 Jul 2024

Toyodome Ai, Mawatari Seiichi, Eguchi Hiromi, Takeda Midori, Kumagai Kotaro, Taniyama Ohki, Ijuin Sho, Sakae Haruka, Tabu Kazuaki, Oda Kohei, Ikeda Masanori, Ido Akio

Abstract excerpt

Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K RASs, which were observed in patients with DAAs re-treatment failure and to consider new therapeutic agents. We used a subgenomic replicon system in which HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Benzopyrans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorenes

Share to Heterocyclic Compounds, 4 or More Rings

Share to Pyrazines

Share to Pyrrolidines

Share to Replicon

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 39013947
DOI: 10.1038/s41598-024-67169-5
PMCID: PMC11252252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors.PMID 39013947Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western ChinaSemantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].Semantic proximity Read ↗

The role of resistance in HCV treatment.Semantic proximity Read ↗

Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus InfectionSemantic proximity Read ↗

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.Semantic proximity Read ↗

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.Semantic proximity Read ↗

[RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.